

JAMA Author Interviews
JAMA Network
Interviews with leading researchers and thinkers in health care about practice-changing research, innovations, and the most pressing issues facing medicine and health care today from JAMA, the Journal of the American Medical Association.
Episodes
Mentioned books

Sep 11, 2024 • 12min
Improving Access to Palliative Care for Patients With Cancer
Palliative care is an essential component to high-quality care for patients with cancer. How can access to palliative care be expanded? Eduardo Bruera, MD, from MD Anderson Cancer Center speaks with JAMA Editor in Chief Kirsten Bibbins-Domingo about 2 new trials in JAMA that address access to care and what more it will take for executives, insurers, and regulators to support palliative care programs. Related Content: Improving Palliative Care Access for Patients With Cancer Telehealth vs In-Person Early Palliative Care for Patients With Advanced Lung Cancer

Sep 5, 2024 • 14min
Balloon Angioplasty for Intracranial Atherosclerotic Stenosis
Join Zhongrong Miao, MD, PhD, a medical expert from Beijing Tiantan Hospital, and Christopher C. Muth, MD, JAMA's Deputy Editor, as they dive into the BASIS randomized clinical trial. They discuss the alarming prevalence of intracranial artery stenosis in Asia and its connection to severe patient outcomes. The podcast explores the advantages of balloon angioplasty combined with aggressive medical management, shedding light on its potential to lower long-term stroke and death risks while calling for improved clinician training to mitigate periprocedural complications.

Aug 29, 2024 • 10min
Concerning Mortality Rate Trends in the US
The abating COVID-19 pandemic brings attention to rising mortality rates from non-COVID causes in the US, a trend that predates the COVID-19 pandemic. Viewpoint author Steven H. Woolf, MD, MPH, discusses this and more with JAMA Executive Editor Gregory Curfman, MD. Related Content: Increasing Mortality Rates in the US, but Not From COVID-19

Aug 22, 2024 • 11min
Menopause-Associated Vasomotor Symptom Treatment With Elinzanetant
Nonhormonal treatments for menopausal vasomotor symptoms may benefit symptomatic patients who cannot take or prefer to avoid systemic hormones. Author JoAnn V. Pinkerton, MD, MSCP, discusses the efficacy and safety of elinzanetant for the treatment of moderate to severe vasomotor symptoms associated with menopause with JAMA Deputy Editor Linda Brubaker, MD, MS. Related Content: Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause A New Era in Menopause Management?

Aug 21, 2024 • 11min
Long COVID in Children
To address the need to characterize long COVID in children and adolescents, the National Institutes of Health funded a pediatric program in the Researching COVID to Enhance Recovery (RECOVER) Initiative. Editorialist Suchitra Rao, MBBS, MSCS, University of Colorado School of Medicine and Children’s Hospital Colorado, Aurora, discusses this and more with JAMA Senior Editor Tracy A. Lieu, MD, MPH. Related Content: Uncovering Long COVID in Children Characterizing Long COVID in Children and Adolescents

Aug 15, 2024 • 9min
Uterus Transplant: Innovation and Considerations
A new study looks at uterus transplant to determine if it is safe, feasible, and results in births of healthy infants. Editorialist Emily Jungheim, MD, MSCI, Northwestern University, discusses this innovative treatment with JAMA Deputy Editor Linda Brubaker, MD, MS. Related Content: Uterus Transplant—The Frontier of Innovative Fertility Treatment Uterus Transplant in Women With Absolute Uterine-Factor Infertility

Aug 7, 2024 • 11min
A Vaping Cessation Text Message Program for Adolescents
Ten percent of US adolescents use e-cigarettes, and many want to quit. However, evidence on the effectiveness of vaping cessation interventions is lacking. Amanda L. Graham, PhD, of the Truth Initiative discusses with JAMA Senior Editor Tracy Lieu, MD, MPH, how a tailored, interactive text message intervention increased vaping cessation among adolescents recruited via social media channels. Related Content: A Vaping Cessation Text Message Program for Adolescent E-Cigarette Users Supporting Adolescents’ Desire to Quit E-Cigarettes What Are E-Cigarettes? Variability in Constituents of E-Cigarette Products Containing Nicotine Analogues E-Cigarette Use in Adults Controversial FDA Decision Authorizes Menthol-Flavored E-Cigarettes Despite Risks to Youth Vaping in Youth E-Cigarette Use in Adolescents and Adults—A JAMA Collection

Aug 1, 2024 • 10min
Diagnostic Accuracy of an Integrated AI Ultrasound Tool for Gestational Age Estimation
Gestational age estimation is foundational for obstetric care. In resource-limited settings, an integrated AI tool allows novice users to improve gestational age estimates. Author Jeffrey Stringer, MD, University of North Carolina, joins JAMA Deputy Editor Linda Brubaker, MD, MS, to discuss Diagnostic Accuracy of an Integrated AI Tool to Estimate Gestational Age From Blind Ultrasound Sweeps. Related Content: Diagnostic Accuracy of an Integrated AI Tool to Estimate Gestational Age From Blind Ultrasound Sweeps Enhancing Obstetric Ultrasonography With Artificial Intelligence in Resource-Limited Settings

Jul 28, 2024 • 15min
Alzheimer Disease Blood Biomarkers
Biomarkers for Alzheimer disease (AD) provide insight into disease processes and may aid clinical diagnosis for individuals with cognitive impairment. Author Stephen Salloway, MD, MS, of Brown University joins JAMA Deputy Editor Christopher Muth, MD, to discuss 2 articles and an accompanying editorial about blood biomarkers for AD and potential implications for clinical practice. Related Content: Are Blood Tests for Alzheimer Disease Ready for Prime Time? Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care Changes in Alzheimer Disease Blood Biomarkers and Associations With Incident All-Cause Dementia

Jul 22, 2024 • 16min
Risankizumab for Ulcerative Colitis
Guest Gilaad G. Kaplan discusses Risankizumab for ulcerative colitis with JAMA Editor. Topics include personalized therapy with monoclonal antibodies targeting IL-23 pathway, phase 3 trial results showing higher remission rates, complexities in comparing risankizumab to placebo, and the importance of precision medicine in treatment strategies.